Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company developing the patented DepoVax(TM) vaccine
adjuvanting platform and product candidates for cancer therapy and infectious
diseases, today announced that Phase I clinical data for DPX-0907, a therapeutic
cancer vaccine, will be presented in the Developmental Therapeutics - Clinical
Pharmacology and Immunotherapy poster session at the American Society of
Clinical Oncology (ASCO) 2012 Annual Meeting. The ASCO Annual Meeting will be
held June 1 - 5, 2012, in Chicago.


The poster presentation will highlight data from the Company's completed Phase I
clinical trial of DPX-0907 in patients with breast, ovarian and prostate cancers
demonstrating that the cancer vaccine is well tolerated and can generate a
targeted antigen-specific, poly-functional CD8 T-cell immune response. 


Details of the poster presentation are as follows:



Abstract  A novel therapeutic cancer vaccine formulation DPX-0907 induces   
#2588:    multifunctional T cell responses in ovarian, breast and prostate 
          cancer patients.                                                 
                                                                            
          Marc Mansour, Ph.D; Immunovaccine's Chief Science Officer         
          Poster Board #7E, S Hall A2                                       
          Monday, June 4, 8:00 a.m. - 12:00 p.m.                            



About Immunovaccine

Immunovaccine Inc. applies its novel vaccine delivery platform to the
development of vaccines for cancer therapy and infectious diseases. The
company's DepoVax(TM) platform is a patented lipid delivery system that presents
antigens plus adjuvant to the immune system for a prolonged period and has the
potential to enhance immune responses. Immunovaccine has advanced its platform
technology and proprietary cancer vaccine into Phase I human clinical trials and
has demonstrated both safety and immunogenicity potential. The Company is also
capitalizing on the broad potential of its delivery platform by creating new
DepoVax-based vaccines through multiple development collaborations. In addition
to the Company's human health vaccine strategy, it continues to capture value
from animal health vaccine applications. Immunovaccine has several key
partnerships in the animal health sector including an agreement with Pfizer
Animal Health, which has licensed the Company's delivery technology platform to
develop vaccines for livestock. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release.